全文获取类型
收费全文 | 1336258篇 |
免费 | 114676篇 |
国内免费 | 6364篇 |
专业分类
耳鼻咽喉 | 16705篇 |
儿科学 | 43005篇 |
妇产科学 | 36554篇 |
基础医学 | 183620篇 |
口腔科学 | 36272篇 |
临床医学 | 120683篇 |
内科学 | 278502篇 |
皮肤病学 | 31886篇 |
神经病学 | 110491篇 |
特种医学 | 55534篇 |
外国民族医学 | 274篇 |
外科学 | 210339篇 |
综合类 | 31527篇 |
现状与发展 | 2篇 |
一般理论 | 414篇 |
预防医学 | 106622篇 |
眼科学 | 28085篇 |
药学 | 93709篇 |
5篇 | |
中国医学 | 2227篇 |
肿瘤学 | 70842篇 |
出版年
2018年 | 13374篇 |
2017年 | 10630篇 |
2016年 | 12794篇 |
2015年 | 14297篇 |
2014年 | 19945篇 |
2013年 | 29734篇 |
2012年 | 36232篇 |
2011年 | 38882篇 |
2010年 | 24369篇 |
2009年 | 23900篇 |
2008年 | 36360篇 |
2007年 | 38771篇 |
2006年 | 39896篇 |
2005年 | 38487篇 |
2004年 | 36721篇 |
2003年 | 35820篇 |
2002年 | 33830篇 |
2001年 | 66052篇 |
2000年 | 67917篇 |
1999年 | 56587篇 |
1998年 | 16723篇 |
1997年 | 15017篇 |
1996年 | 16014篇 |
1995年 | 16232篇 |
1994年 | 15098篇 |
1993年 | 14153篇 |
1992年 | 47098篇 |
1991年 | 45747篇 |
1990年 | 43970篇 |
1989年 | 41815篇 |
1988年 | 38758篇 |
1987年 | 38081篇 |
1986年 | 35859篇 |
1985年 | 34635篇 |
1984年 | 26358篇 |
1983年 | 22108篇 |
1982年 | 13847篇 |
1981年 | 12447篇 |
1980年 | 11718篇 |
1979年 | 23544篇 |
1978年 | 17072篇 |
1977年 | 14385篇 |
1976年 | 13182篇 |
1975年 | 13722篇 |
1974年 | 16093篇 |
1973年 | 15396篇 |
1972年 | 14173篇 |
1971年 | 13036篇 |
1970年 | 11880篇 |
1969年 | 11101篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
201.
202.
203.
J.A. Hannam S.J. Mitchell D. Cumin C. Frampton A.F. Merry M.R. Moore C.J. Kruger 《British journal of anaesthesia》2019,122(2):198-205
Background
Etomidate is frequently selected over propofol for induction of anaesthesia because of a putatively favourable haemodynamic profile, but data confirming this perception are limited.Methods
Patients undergoing cardiac surgery were randomised to induction of anaesthesia with propofol or etomidate. Phase I (n=75) was conducted as open-label, whereas Phase II (n=75) was double blind. Mean arterial blood pressure (MAP) and boluses of vasopressor administered after induction were recorded. The primary endpoint was the area under the curve below baseline MAP (MAP-time integral) during the 10 min after induction. Secondary endpoints were the use of vasopressors over the same period, and the effect of blinding on the aforementioned endpoints. Groups were compared using regression models with phase and anaesthetist as factors.Results
The mean difference between etomidate and propofol in the MAP-time integral below baseline was 2244 mm Hg s (95% confidence interval, 581–3906; P=0.009), representing a 34% greater reduction with propofol. Overall, vasopressors were used in 10/75 patients in the etomidate group vs 21/75 in the propofol group (P=0.38), and in 20/74 patients during the blinded phase vs 11/76 during the open-label phase (P=0.31). The interaction between randomisation and phase (open-labelled or blinded) was not significant for either primary (P=0.73) or secondary endpoints (P=0.90).Conclusions
Propofol caused a 34% greater reduction in MAP-time integral from baseline after induction of anaesthesia than etomidate, despite more frequent use of vasopressors with propofol, confirming the superior haemodynamic profile of etomidate in this context. The proportion of patients receiving vasopressors increased slightly, albeit not significantly, in both groups in the blinded phase.Clinical trial registration
Australian and New Zealand Clinical Trials Registry, ACTRN12614000717651. 相似文献204.
205.
Renal Denervation for Treatment of Cardiac Arrhythmias: State of the Art and Future Directions
下载免费PDF全文
![点击此处可从《Journal of cardiovascular electrophysiology》网站下载免费的PDF全文](/ch/ext_images/free.gif)
JEDRZEJ KOSIUK M.D. SEBASTIAN HILBERT M.D. EVGENY POKUSHALOV M.D. GERHARD HINDRICKS M.D. Ph.D. JONATHAN S. STEINBERG M.D. ANDREAS BOLLMANN M.D. Ph.D. 《Journal of cardiovascular electrophysiology》2015,26(2):233-238
Renal Denervation for Treatment of Cardiac Arrhythmias . It has now been more than a quarter of a century since modulation of the sympathetic nervous system was proposed for the treatment of cardiac arrhythmias of different origins. But it has also been some time since some of the early surgical attempts have been abandoned. With the development of ablation techniques, however, new approaches and targets have been recently introduced that have revolutionized our way of thinking about sympathetic modulation. Renal nerve ablation technology is now being successfully used for the treatment of resistant hypertension, but the indication spectrum might broaden and new therapeutic options might arise in the near future. This review focuses on the possible impact of renal sympathetic system modulation on cardiac arrhythmias, the current evidence supporting this approach, and the ongoing trials of this method in electrophysiological laboratories. We will discuss the potential roles that sympathetic modulation may play in the future. 相似文献
206.
207.
208.
209.
210.